Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy

Rhea-AI Summary

Pasithea Clinics has launched IV ketamine infusion therapy in Knightsbridge, London, targeting mental health disorders. This initiative is part of Pasithea Therapeutics Corp.'s broader mission to find effective treatments for psychiatric conditions. The therapy is particularly aimed at treatment-resistant depression and PTSD, with studies indicating a clinical response rate of up to 70%. Partnering with ZEN Healthcare in the U.K. and The IV Doc in the U.S., Pasithea is expanding access to these treatments, addressing the growing mental health crisis.

Positive

• Launch of IV ketamine therapy could attract new patients.
• High clinical response rate (up to 70%) for ketamine treatment.
• Partnerships with ZEN Healthcare and The IV Doc expand treatment access.

Negative

• None.

– Pasithea Clinics commences IV ketamine infusion therapy in Knightsbridge, London, for the treatment of mental health disorders –

MIAMI BEACH, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Pasithea Clinics, its wholly owned subsidiary, has administered intravenous (“IV”) ketamine therapy to its first patients. In sub-anesthetic doses, ketamine has shown to be highly effective at treating some psychiatric disorders, such as treatment-resistant depression and post-traumatic stress disorder.

“With major depression the leading cause of long-term disability worldwide and mental health cases on the rise, new therapies are urgently needed for patients who do not respond to traditional treatments. Today, we are thrilled to announce that we administered our first IV ketamine infusion therapy to patients with treatment-resistant depression,” stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.

“This is a significant milestone for Pasithea Clinics and for patients in the U.K. suffering with mental health conditions. Decades of evidence supports the efficacy of ketamine in improving symptoms for some mental health disorders, and studies have shown that up to 70% of those who receive IV ketamine treatment will eventually show a clinical response. We are excited to continue providing treatment to patients deemed eligible to receive it,” concluded Dr. Reis Marques.

Ketamine is a U.S. Food and Drug Administration (“FDA”) approved drug introduced as an anesthetic more than 50 years ago. It has recently been repurposed in significantly lower doses for the treatment of psychiatric disorders and is now gaining ground as a promising treatment for mental health disorders. In certain psychiatric conditions, such as treatment-resistant depression (“TRD”) and post-traumatic stress disorder (“PTSD”), it has shown remarkable efficacy and a rapid and sustained effect.

Pasithea has clinical partnerships to administer its IV ketamine treatment. In the U.K., it has partnered with ZEN Healthcare – a network of health clinics in London. In the U.S., it has partnered with The IV Doc, Inc. to provide in-home IV ketamine infusions. Both partnerships offer rapid exposure and expansion opportunities.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com

Pasithea Therapeutics Corp. Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

What is the significance of Pasithea Clinics starting IV ketamine infusion therapy?

The launch of IV ketamine therapy is significant as it provides new treatment options for patients with mental health disorders, particularly those who are treatment-resistant.

What mental health conditions does IV ketamine infusion therapy target?

IV ketamine infusion therapy primarily targets treatment-resistant depression and post-traumatic stress disorder (PTSD).

What is the expected clinical response rate for IV ketamine treatment?

Studies indicate that up to 70% of patients receiving IV ketamine treatment may show a clinical response.

Which partnerships has Pasithea established for ketamine treatment?

Pasithea has partnered with ZEN Healthcare in the U.K. and The IV Doc in the U.S. to provide IV ketamine treatments.

When did Pasithea Clinics administer their first IV ketamine therapy?

Pasithea Clinics administered their first IV ketamine infusion therapy to patients on October 27, 2021.